CSIMarket
Company Name or Ticker Symbol
Search for other Categories
 


Exelixis, Inc.  (EXEL)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
 
 

EXEL's Revenue Year on Year Growth by Quarter and Year

Exelixis,'s Revenue results by quarter and year



Select the Comparisons : Select the Ratio:                        
EXEL Revenue (in millions $) FY 2017 FY 2016 FY 2015 FY 2014
IV Quarter December - 77.58 9.94 7.35
III Quarter September - 62.19 9.85 6.29
II Quarter June - 36.25 7.99 6.56
I Quarter March 80.89 15.43 9.39 4.91
FY   80.89 191.45 37.17 25.11

Financial Statements
Exelixis,'s first quarter 2017 Revenue $ 80.89 millions EXEL's Income Statement
Exelixis,'s first quarter 2016 Revenue $ 15.43 millions Quarterly EXEL's Income Statement
EXEL's Growth by Division See EXEL's Growth by Segment

EXEL Revenue ( Y/Y Growth %) 2017
2016 2015 2014
IV Quarter December - 680.48 % 35.24 % 950 %
III Quarter September - 531.37 % 56.6 % 14.99 %
II Quarter June - 353.69 % 21.8 % -44.69 %
I Quarter March 424.22 % 64.32 % 91.24 % -37.13 %
FY   - 415.07 % 48.03 % -



EXEL Revenue Growth Comment
Exelixis, Inc. achieved in the first quarter, above Company average Revenue surge of 424.22% year on year, to $ 80.89 millions.

Looking into first quarter results within Medical Laboratories industry 3 other companies have achieved higher Revenue growth. While Exelixis, Inc.' s Revenue doubling of 424.22% ranks overall at the positon no. 74 in the first quarter.



Revenue Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #4
Healthcare Sector #19
S&P 500 #74
Revenue Y/Y Growth Statistics
High Average Low
945.95 % 205.15 % -91 %
(Jan 02 2015)   (Dec 27 2013)

You need to upgrade your Flash Player

Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
EXEL's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for EXEL's Competitors
Revenue Growth for Exelixis,'s Suppliers
Revenue Growth for EXEL's Customers

You may also want to know
EXEL's Annual Growth Rates EXEL's Profitability Ratios EXEL's Asset Turnover Ratio EXEL's Dividend Growth
EXEL's Roe EXEL's Valuation Ratios EXEL's Financial Strength Ratios EXEL's Dividend Payout Ratio
EXEL's Roa EXEL's Inventory Turnover Ratio EXEL's Growth Rates EXEL's Dividend Comparisons



Companies with similar Revenue doubling for the quarter ending Mar 31 2017 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2017
Biocept Inc  660.30 %$ 660.298 millions
Geovax Labs, Inc.  521.29 %$ 521.292 millions
Cytomx Therapeutics, Inc.  424.20 %$ 424.202 millions
Sientra, Inc.  409.11 %$ 409.109 millions
Sorrento Therapeutics, Inc.  393.32 %$ 393.320 millions
Bluebird Bio, Inc.  355.77 %$ 355.771 millions
Agenus Inc  352.36 %$ 352.365 millions
Protalix Biotherapeutics, Inc.  325.48 %$ 325.479 millions
Lifestyle Medical Network, Inc.  319.44 %$ 319.438 millions
Orexigen Therapeutics, Inc.  280.39 %$ 280.389 millions
Intellia Therapeutics, Inc.  249.75 %$ 249.747 millions
Biolargo, Inc.  230.06 %$ 230.060 millions
Corbus Pharmaceuticals Holdings, Inc.  226.20 %$ 226.199 millions
Exact Sciences Corp  226.01 %$ 226.006 millions
Accelerate Diagnostics, Inc.  225.15 %$ 225.153 millions


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2017 CSIMarket, Inc. All rights reserved. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)
Intraday Data provided by Barchart and subject to terms of use. To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Stock Price, historical and current end-of-day data provided by eoddata. Intraday data delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Barchart and Eoddata. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com